BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) are prescription medicines used together to treat people with a type of skin cancer called melanoma.

Braftovi is a medicine for treating certain cancers when their cells have a mutation (change) in their genes called ‘BRAF V600’.

Braftovi is used in combination with another medicine, binimetinib  to treat melanoma (a skin cancer) that cannot be removed by surgery or has spread.

It is also used in combination with the medicine cetuximab to treat colorectal cancer (cancer of the large bowel or rectum) with the BRAF V600E version of the mutation, when it has spread elsewhere in the body and has previously been treated with other medicines. It contains the active substance encorafenib.

The European Medicines Agency therefore decided that Braftovi’s benefits are greater than its risks and it can be authorised for use in the EU.

Colorectal cancer

Download for details: BRAFTOVI